• Home
  • Search Results
  • Blood pressure-renal blood flow relationships in conscious angiotensin II- and phenylephrine-infused rats.

Blood pressure-renal blood flow relationships in conscious angiotensin II- and phenylephrine-infused rats.

American journal of physiology. Renal physiology (2013-07-05)
Aaron J Polichnowski, Karen A Griffin, Jianrui Long, Geoffrey A Williamson, Anil K Bidani

Chronic ANG II infusion in rodents is widely used as an experimental model of hypertension, yet very limited data are available describing the resulting blood pressure-renal blood flow (BP-RBF) relationships in conscious rats. Accordingly, male Sprague-Dawley rats (n = 19) were instrumented for chronic measurements of BP (radiotelemetry) and RBF (Transonic Systems, Ithaca, NY). One week later, two or three separate 2-h recordings of BP and RBF were obtained in conscious rats at 24-h intervals, in addition to separate 24-h BP recordings. Rats were then administered either ANG II (n = 11, 125 ng·kg(-1)·min(-1)) or phenylephrine (PE; n = 8, 50 mg·kg(-1)·day(-1)) as a control, ANG II-independent, pressor agent. Three days later the BP-RBF and 24-h BP recordings were repeated over several days. Despite similar increases in BP, PE led to significantly greater BP lability at the heart beat and very low frequency bandwidths. Conversely, ANG II, but not PE, caused significant renal vasoconstriction (a 62% increase in renal vascular resistance and a 21% decrease in RBF) and increased variability in BP-RBF relationships. Transfer function analysis of BP (input) and RBF (output) were consistent with a significant potentiation of the renal myogenic mechanism during ANG II administration, likely contributing, in part, to the exaggerated reductions in RBF during periods of BP elevations. We conclude that relatively equipressor doses of ANG II and PE lead to greatly different ambient BP profiles and effects on the renal vasculature when assessed in conscious rats. These data may have important implications regarding the pathogenesis of hypertension-induced injury in these models of hypertension.

Product Number
Product Description

R-(-)-Phenylephrine hydrochloride solution, 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®
(R)-(−)-Phenylephrine hydrochloride, powder
(R)-(−)-Phenylephrine hydrochloride, analytical standard
Phenylephrine hydrochloride for peak identification, European Pharmacopoeia (EP) Reference Standard
Phenylephrine Hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material